Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

AstraZeneca PLC - American Depositary Shares (NY:AZN)

157.97 -11.67 (-6.88%)

Official Closing Price Updated: 7:00 PM EDT, Aug 3, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	16,313,058
Open	157.16
Bid (Size)	158.00 (200)
Ask (Size)	158.30 (200)
Prev. Close	169.64
Today's Range	153.41 - 159.72
52wk Range	153.41 - 212.71
Shares Outstanding	N/A
Dividend Yield	0.59%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

July 28, 2026

From Pomerantz LLP

Via GlobeNewswire

Astrazeneca Q2 Earnings Call Highlights ↗

July 27, 2026

Astrazeneca (NYSE:AZN) reported first-half 2026 revenue growth of 6% at constant exchange rates, or 11% excluding the effects of generic competition on Farxiga and Brilinta, while core earnings per...

Via MarketBeat

Performance

YTD	-16.2%	-16.2%
1 Month	-16.9%	-16.9%
3 Month	-13.9%	-13.9%
6 Month	-16.2%	-16.2%
1 Year	-16.2%	-16.2%

More News

Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers

July 27, 2026

From AstraZeneca

Via Business Wire

AstraZeneca results: H1 and Q2 2026

July 27, 2026

From AstraZeneca

Via Business Wire

AZN Investors Have Opportunity to Join AstraZeneca PLC Fraud Investigation with the Schall Law Firm

July 22, 2026

From The Schall Law Firm

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AstraZeneca PLC- AZN

July 21, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

July 14, 2026

From Pomerantz LLP

Via GlobeNewswire

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions ↗

July 13, 2026

Via MarketBeat

AZN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into AstraZeneca (AZN)

July 13, 2026

From Levi & Korsinsky, LLP

Via Business Wire

AstraZeneca Updates 2030 Sustainability Goals as AI and Emissions Cuts Take Center Stage ↗

July 11, 2026

Via MarketBeat

IEFA vs. VXUS: Both Are Cheap. Both Are Broad. Here Is the Key Difference Long-Term Investors Need to Understand. ↗

July 02, 2026

Via The Motley Fool

AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care

June 24, 2026

From AstraZeneca

Via Business Wire

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Targets Next Wave of DNA Damage Response Cancer Therapies

June 22, 2026

Via Investor Brand Network

Next-Generation DNA Repair Therapies Open New Frontiers in Oncology

June 22, 2026

Via Investor Brand Network

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

June 12, 2026

From AstraZeneca

Via Business Wire

IXUS vs. IEFA: Which International ETF Is Better for Most Investors? ↗

June 10, 2026

Via The Motley Fool

Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial

June 02, 2026

From AstraZeneca

Via Business Wire

IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial

June 01, 2026

From AstraZeneca

Via Business Wire

IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer

May 28, 2026

From AstraZeneca

Via Business Wire

Marathon Halves Its Copa Stake—The Panama Hub Advantage Still Stands ↗

May 23, 2026

Via The Motley Fool

DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates

May 22, 2026

From AstraZeneca

Via Business Wire

AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026

May 22, 2026

From AstraZeneca

Via Business Wire

3 International ETFs for Investors Looking Beyond U.S. Stocks ↗

May 18, 2026

Via The Motley Fool

As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade ↗

May 18, 2026

Via MarketBeat

BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension

May 18, 2026

From AstraZeneca

Via Business Wire

Frequently Asked Questions

Is AstraZeneca PLC - American Depositary Shares publicly traded?

Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.

What exchange does AstraZeneca PLC - American Depositary Shares trade on?

AstraZeneca PLC - American Depositary Shares trades on the New York Stock Exchange

What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?

The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the New York Stock Exchange

What is the current price of AstraZeneca PLC - American Depositary Shares?

The current price of AstraZeneca PLC - American Depositary Shares is 157.97

When was AstraZeneca PLC - American Depositary Shares last traded?

The last trade of AstraZeneca PLC - American Depositary Shares was at 08/03/26 07:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.